Aesica Joins Forces with Britest
News Feb 15, 2013
Aesica has announced that it will be joining Britest in a collaboration where members share knowledge and risk in defining innovative solutions to key manufacturing challenges.
Britest has already engaged with 22 leading global chemical and pharmaceutical organizations together with a number of academic organizations.
The partnerships are designed to utilize and further develop Britest’s innovative tools and methodologies to support whole process understanding.
In particular, Aesica will be utilizing Britest’s expertise to identify new approaches and technologies that drive major improvements in API manufacturing processes.
The Aesica Innovation Board (AIB) aims to identify and commercialize new innovative technologies that help to bridge the growing R&D gap though industry and academic collaborations.
Joining Britest will increase the AIB’s access to applicable, relevant technologies and strengthen the organizations relationships throughout the industry.
Dr Barrie Rhodes, Aesica Director of Technology Development said: “At Aesica we aspire to develop and implement new technologies and improve processes to support business growth. Following the successful demonstration of the Britest approach on a key Active Pharmaceutical Ingredient process at our Cramlington site, we are now looking forward to engaging fully in the Britest collaboration and implementing the Britest approach across a range of processes.”
Sue Fleet, Britest CEO said: “I am delighted to welcome Aesica Pharmaceuticals as our latest company member. With a clear focus on innovation and collaboration, we look forward to supporting Barrie and his colleagues at Aesica in driving innovative thinking and deriving full value from their membership of Britest.”
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018